Serveur d'exploration sur le lymphœdème

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

P‐64 Cutaneous epitheliotropic lymphoma in a dog: treatment with oral pentoxifylline

Identifieur interne : 008A04 ( Main/Exploration ); précédent : 008A03; suivant : 008A05

P‐64 Cutaneous epitheliotropic lymphoma in a dog: treatment with oral pentoxifylline

Auteurs : G. A. Manigot [Argentine]

Source :

RBID : ISTEX:AC406EE8BCF00DFC4C69E8522F002F5D10B35CB7

Abstract

A 9‐year‐old intact female Shih Tzu‐mix dog with a generalized form of cutaneous epitheliotropic lymphoma with vasculitis lesions was treated with oral pentoxifylline (200 mg twice daily) after failure to control the process with prednisone (2 mg/kg). The dog showed signs of internal lymph node involvement and hepatic invasion. Lesions included all three typically described stages at the same time with a 1‐year period of a highly pruritic erythematous dermatitis. At the time of consultation, the dog showed erythroderma, mild scaling, ulcerated nodules, crusted plaques, hypopigmentation of the planum nasale, lips and eyelids, and vasculitis of the footpads. Biopsy samples and cytology were diagnostic for cutaneous epitheliotropic lymphoma. Therapy consisted of prednisolone at a dosage of 2 mg/kg, but it failed to control the progression of the disease. Vasculitis lesions increased in number and area, thus pentoxifylline (200 mg twice daily) was administered. The use of pentoxifylline resulted in a marked improvement of the skin condition, decreasing the erythroderma, healing the vasculitis lesions and controlling the pruritus. The dog died 2 months after the initial clinical, cytological and histopathological diagnosis, because of respiratory complications. More research needs to be done on dogs with terminal cases of cutaneous epitheliotropic lymphoma that fail to be controlled with the usual therapy. Those dogs might benefit from the use of pentoxifylline. Funding: Self‐funded.

Url:
DOI: 10.1111/j.1365-3164.2004.00414_64.x


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">P‐64 Cutaneous epitheliotropic lymphoma in a dog: treatment with oral pentoxifylline</title>
<author>
<name sortKey="Manigot, G A" sort="Manigot, G A" uniqKey="Manigot G" first="G. A." last="Manigot">G. A. Manigot</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:AC406EE8BCF00DFC4C69E8522F002F5D10B35CB7</idno>
<date when="2004" year="2004">2004</date>
<idno type="doi">10.1111/j.1365-3164.2004.00414_64.x</idno>
<idno type="url">https://api.istex.fr/document/AC406EE8BCF00DFC4C69E8522F002F5D10B35CB7/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">005108</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">005108</idno>
<idno type="wicri:Area/Istex/Curation">005108</idno>
<idno type="wicri:Area/Istex/Checkpoint">001E88</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001E88</idno>
<idno type="wicri:doubleKey">0959-4493:2004:Manigot G:p:cutaneous:epitheliotropic</idno>
<idno type="wicri:Area/Main/Merge">008C68</idno>
<idno type="wicri:Area/Main/Curation">008A04</idno>
<idno type="wicri:Area/Main/Exploration">008A04</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main">P‐64 
Cutaneous epitheliotropic lymphoma in a dog: treatment with oral pentoxifylline</title>
<author>
<name sortKey="Manigot, G A" sort="Manigot, G A" uniqKey="Manigot G" first="G. A." last="Manigot">G. A. Manigot</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Argentine</country>
<wicri:regionArea>Allergy and Dermatology Referral Service, Buenos Aires</wicri:regionArea>
<wicri:noRegion>Buenos Aires</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j" type="main">Veterinary Dermatology</title>
<title level="j" type="alt">VETERINARY DERMATOLOGY</title>
<idno type="ISSN">0959-4493</idno>
<idno type="eISSN">1365-3164</idno>
<imprint>
<biblScope unit="vol">15</biblScope>
<biblScope unit="page" from="61">61</biblScope>
<biblScope unit="page" to="61">61</biblScope>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2004-08">2004-08</date>
</imprint>
<idno type="ISSN">0959-4493</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0959-4493</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">A 9‐year‐old intact female Shih Tzu‐mix dog with a generalized form of cutaneous epitheliotropic lymphoma with vasculitis lesions was treated with oral pentoxifylline (200 mg twice daily) after failure to control the process with prednisone (2 mg/kg). The dog showed signs of internal lymph node involvement and hepatic invasion. Lesions included all three typically described stages at the same time with a 1‐year period of a highly pruritic erythematous dermatitis. At the time of consultation, the dog showed erythroderma, mild scaling, ulcerated nodules, crusted plaques, hypopigmentation of the planum nasale, lips and eyelids, and vasculitis of the footpads. Biopsy samples and cytology were diagnostic for cutaneous epitheliotropic lymphoma. Therapy consisted of prednisolone at a dosage of 2 mg/kg, but it failed to control the progression of the disease. Vasculitis lesions increased in number and area, thus pentoxifylline (200 mg twice daily) was administered. The use of pentoxifylline resulted in a marked improvement of the skin condition, decreasing the erythroderma, healing the vasculitis lesions and controlling the pruritus. The dog died 2 months after the initial clinical, cytological and histopathological diagnosis, because of respiratory complications. More research needs to be done on dogs with terminal cases of cutaneous epitheliotropic lymphoma that fail to be controlled with the usual therapy. Those dogs might benefit from the use of pentoxifylline. Funding: Self‐funded.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Argentine</li>
</country>
</list>
<tree>
<country name="Argentine">
<noRegion>
<name sortKey="Manigot, G A" sort="Manigot, G A" uniqKey="Manigot G" first="G. A." last="Manigot">G. A. Manigot</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008A04 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008A04 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:AC406EE8BCF00DFC4C69E8522F002F5D10B35CB7
   |texte=   P‐64 Cutaneous epitheliotropic lymphoma in a dog: treatment with oral pentoxifylline
}}

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024